Trials / Completed
CompletedNCT03664635
MB-CART20.1 Lymphoma
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART20.1 in Patients with Relapsed or Resistant CD20 Positive B-NHL
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Miltenyi Biomedicine GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a phase I/II trial to assess safety, dose finding and feasibility of ex vivo generated MB-CART20.1 cells in patients with relapsed or refractory CD20 positive B-NHL.
Detailed description
MB-CART20.1 consists of autologous Anti-CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in Non-Hodgkin-Lymphoma (NHL)
Conditions
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Non-Hodgkin's Lymphoma
- B-cell Lymphoma Refractory
- B-cell Lymphoma Recurrent
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MB-CART20.1 | MB-CART20.1 consists of autologous CD20 Chimeric Antigen Receptor (CAR) transduced CD4 /CD8 enriched T cells targeting CD20-positive tumor cells in NHL |
Timeline
- Start date
- 2018-09-25
- Primary completion
- 2024-09-17
- Completion
- 2024-09-17
- First posted
- 2018-09-10
- Last updated
- 2024-11-21
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03664635. Inclusion in this directory is not an endorsement.